Logo image of VRCA

VERRICA PHARMACEUTICALS INC (VRCA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VRCA - US92511W2070 - Common Stock

6.73 USD
-0.82 (-10.86%)
Last: 12/2/2025, 8:14:26 PM
6.52 USD
-0.21 (-3.12%)
After Hours: 12/2/2025, 8:14:26 PM
Fundamental Rating

2

Overall VRCA gets a fundamental rating of 2 out of 10. We evaluated VRCA against 192 industry peers in the Pharmaceuticals industry. VRCA may be in some trouble as it scores bad on both profitability and health. VRCA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VRCA had negative earnings in the past year.
VRCA had a negative operating cash flow in the past year.
In the past 5 years VRCA always reported negative net income.
In the past 5 years VRCA always reported negative operating cash flow.
VRCA Yearly Net Income VS EBIT VS OCF VS FCFVRCA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -124.63%, VRCA is doing worse than 81.77% of the companies in the same industry.
Industry RankSector Rank
ROA -124.63%
ROE N/A
ROIC N/A
ROA(3y)-92.78%
ROA(5y)-75.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRCA Yearly ROA, ROE, ROICVRCA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

The Gross Margin of VRCA (86.46%) is better than 89.06% of its industry peers.
VRCA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRCA Yearly Profit, Operating, Gross MarginsVRCA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

1

2. Health

2.1 Basic Checks

VRCA does not have a ROIC to compare to the WACC, probably because it is not profitable.
VRCA has more shares outstanding than it did 1 year ago.
VRCA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, VRCA has a worse debt to assets ratio.
VRCA Yearly Shares OutstandingVRCA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
VRCA Yearly Total Debt VS Total AssetsVRCA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -13.33, we must say that VRCA is in the distress zone and has some risk of bankruptcy.
VRCA has a worse Altman-Z score (-13.33) than 78.13% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.33
ROIC/WACCN/A
WACC12.2%
VRCA Yearly LT Debt VS Equity VS FCFVRCA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 1.26 indicates that VRCA should not have too much problems paying its short term obligations.
The Current ratio of VRCA (1.26) is worse than 78.65% of its industry peers.
VRCA has a Quick Ratio of 1.17. This is a normal value and indicates that VRCA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.17, VRCA is doing worse than 72.40% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.26
Quick Ratio 1.17
VRCA Yearly Current Assets VS Current LiabilitesVRCA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.37% over the past year.
Looking at the last year, VRCA shows a very strong growth in Revenue. The Revenue has grown by 47.66%.
Measured over the past years, VRCA shows a very negative growth in Revenue. The Revenue has been decreasing by -14.25% on average per year.
EPS 1Y (TTM)64.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.39%
Revenue 1Y (TTM)47.66%
Revenue growth 3Y-14.25%
Revenue growth 5YN/A
Sales Q2Q%905.39%

3.2 Future

Based on estimates for the next years, VRCA will show a very strong growth in Earnings Per Share. The EPS will grow by 21.45% on average per year.
Based on estimates for the next years, VRCA will show a very strong growth in Revenue. The Revenue will grow by 89.53% on average per year.
EPS Next Y88.63%
EPS Next 2Y33.82%
EPS Next 3Y25.82%
EPS Next 5Y21.45%
Revenue Next Year288.59%
Revenue Next 2Y109.41%
Revenue Next 3Y89.18%
Revenue Next 5Y89.53%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VRCA Yearly Revenue VS EstimatesVRCA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
VRCA Yearly EPS VS EstimatesVRCA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VRCA. In the last year negative earnings were reported.
Also next year VRCA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRCA Price Earnings VS Forward Price EarningsVRCA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRCA Per share dataVRCA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

VRCA's earnings are expected to grow with 25.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.82%
EPS Next 3Y25.82%

More info and screens

0

5. Dividend

5.1 Amount

VRCA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERRICA PHARMACEUTICALS INC

NASDAQ:VRCA (12/2/2025, 8:14:26 PM)

After market: 6.52 -0.21 (-3.12%)

6.73

-0.82 (-10.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-09 2026-03-09/amc
Inst Owners26.38%
Inst Owner Change-90.1%
Ins Owners54.18%
Ins Owner Change16.07%
Market Cap63.87M
Revenue(TTM)7.57M
Net Income(TTM)-48.74M
Analysts78.18
Price Target16.66 (147.55%)
Short Float %12.65%
Short Ratio1.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)51.11%
Min EPS beat(2)-0.55%
Max EPS beat(2)102.78%
EPS beat(4)2
Avg EPS beat(4)20.42%
Min EPS beat(4)-30.9%
Max EPS beat(4)102.78%
EPS beat(8)4
Avg EPS beat(8)5.32%
EPS beat(12)7
Avg EPS beat(12)17.31%
EPS beat(16)10
Avg EPS beat(16)16.92%
Revenue beat(2)2
Avg Revenue beat(2)112.72%
Min Revenue beat(2)33.57%
Max Revenue beat(2)191.87%
Revenue beat(4)2
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-137.73%
Max Revenue beat(4)191.87%
Revenue beat(8)6
Avg Revenue beat(8)80.6%
Revenue beat(12)8
Avg Revenue beat(12)59.58%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.89%
PT rev (3m)8.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)50.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)18.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.34
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.41
EYN/A
EPS(NY)-2.39
Fwd EYN/A
FCF(TTM)-5.02
FCFYN/A
OCF(TTM)-5.02
OCFYN/A
SpS1.55
BVpS-1.84
TBVpS-1.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -124.63%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.46%
FCFM N/A
ROA(3y)-92.78%
ROA(5y)-75.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.42%
Cap/Sales 0.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.26
Quick Ratio 1.17
Altman-Z -13.33
F-Score5
WACC12.2%
ROIC/WACCN/A
Cap/Depr(3y)45.1%
Cap/Depr(5y)835.39%
Cap/Sales(3y)3.58%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.39%
EPS Next Y88.63%
EPS Next 2Y33.82%
EPS Next 3Y25.82%
EPS Next 5Y21.45%
Revenue 1Y (TTM)47.66%
Revenue growth 3Y-14.25%
Revenue growth 5YN/A
Sales Q2Q%905.39%
Revenue Next Year288.59%
Revenue Next 2Y109.41%
Revenue Next 3Y89.18%
Revenue Next 5Y89.53%
EBIT growth 1Y50.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.93%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-278.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-284.57%
OCF growth 3YN/A
OCF growth 5YN/A

VERRICA PHARMACEUTICALS INC / VRCA FAQ

What is the ChartMill fundamental rating of VERRICA PHARMACEUTICALS INC (VRCA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VRCA.


What is the valuation status for VRCA stock?

ChartMill assigns a valuation rating of 1 / 10 to VERRICA PHARMACEUTICALS INC (VRCA). This can be considered as Overvalued.


Can you provide the profitability details for VERRICA PHARMACEUTICALS INC?

VERRICA PHARMACEUTICALS INC (VRCA) has a profitability rating of 1 / 10.